Visugromab (CTL-002) is an IgG4 monoclonal antibody designed to neutralize Growth Differentiation Factor 15 (GDF-15). This antibody has demonstrated synergistic anticancer effects when used in combination with the anti-PD1 antibody Nivolumab. It is particularly effective in treating PD-1/PD-L1 relapsed or refractory metastatic solid tumors, offering a promising therapeutic option for advanced cancer management.
Visugromab (CTL-002) is an IgG4 monoclonal antibody designed to neutralize Growth Differentiation Factor 15 (GDF-15). This antibody has demonstrated synergistic anticancer effects when used in combination with the anti-PD1 antibody Nivolumab. It is particularly effective in treating PD-1/PD-L1 relapsed or refractory metastatic solid tumors, offering a promising therapeutic option for advanced cancer management.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
